{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:04:46Z","timestamp":1792098286932,"version":"4.4.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ctrv.2017.01.009","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T02:00:15Z","timestamp":1486778415000},"page":"99-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Targeting the programmed death-1 pathway in lymphoid neoplasms"],"prefix":"10.1016","volume":"54","author":[{"given":"Chi Young","family":"Ok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2017.01.009_b0005","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1126\/science.169.3950.1042","article-title":"A theory of self-nonself discrimination","volume":"169","author":"Bretscher","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2017.01.009_b0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/85251","article-title":"The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function","volume":"2","author":"Coyle","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily\u2013CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.01.009_b0020","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2017.01.009_b0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.01.009_b0030","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-065X.2008.00666.x","article-title":"Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future","volume":"224","author":"Daeron","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ctrv.2017.01.009_b0040","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1096\/fj.09-131367","article-title":"Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis","volume":"23","author":"El Firar","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.ctrv.2017.01.009_b0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/gb-2005-6-6-223","article-title":"The B7 family of immune-regulatory ligands","volume":"6","author":"Collins","year":"2005","journal-title":"Genome Biol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7\u20131 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.ctrv.2017.01.009_b0055","doi-asserted-by":"crossref","first-page":"656340","DOI":"10.1155\/2012\/656340","article-title":"Programmed death ligand 2 in cancer-induced immune suppression","volume":"2012","author":"Rozali","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","article-title":"Structural and functional analysis of the costimulatory receptor programmed death-1","volume":"20","author":"Zhang","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.ctrv.2017.01.009_b0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4049\/jimmunol.170.2.711","article-title":"Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses","volume":"170","author":"Bennett","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0070","doi-asserted-by":"crossref","first-page":"17765","DOI":"10.1073\/pnas.0708767104","article-title":"Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability","volume":"104","author":"Pentcheva-Hoang","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2017.01.009_b0075","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ctrv.2017.01.009_b0085","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1002\/eji.200526347","article-title":"PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion","volume":"35","author":"Saunders","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/PPO.0000000000000059","article-title":"Biochemical signaling of PD-1 on T cells and its functional implications","volume":"20","author":"Boussiotis","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.ctrv.2017.01.009_b0095","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2017.01.009_b0100","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0105","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.4161\/cc.22135","article-title":"PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A","volume":"11","author":"Patsoukis","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ctrv.2017.01.009_b0110","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1146\/annurev.immunol.20.100301.064807","article-title":"Protein kinase C(theta) in T cell activation","volume":"20","author":"Isakov","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0115","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2017.01.009_b0120","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","article-title":"PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2","volume":"32","author":"Carter","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0125","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2017.01.009_b0130","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7\u2013H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0135","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2017.01.009_b0140","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0145","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7\u2013H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2017.01.009_b0150","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.humpath.2007.11.012","article-title":"Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia","volume":"39","author":"Xerri","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0155","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.molimm.2011.06.436","article-title":"PD-L2 is expressed on activated human T cells and regulates their function","volume":"48","author":"Messal","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0160","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0165","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7\u2013H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2017.01.009_b0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0175","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.01.009_b0180","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.ctrv.2017.01.009_b0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.01.009_b0190","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/2326-6066.CIR-15-0116","article-title":"PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells","volume":"3","author":"Mahoney","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.01.009_b0200","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8010","article-title":"Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L\/3L NSCLC (POPLAR)","volume":"33","author":"Spira","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0205","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0210","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0215","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0220","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0225","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0230","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0235","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0240","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1093\/emboj\/16.21.6478","article-title":"Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade","volume":"16","author":"Kieser","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.ctrv.2017.01.009_b0245","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2013-03-489708","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly","volume":"122","author":"Ok","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0250","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0255","doi-asserted-by":"crossref","first-page":"e78812","DOI":"10.1371\/journal.pone.0078812","article-title":"Nodular lymphocyte predominant hodgkin lymphoma and T cell\/histiocyte rich large B cell lymphoma\u2013endpoints of a spectrum of one disease?","volume":"8","author":"Hartmann","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2017.01.009_b0260","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0265","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.01.009_b0270","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7\u2013H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2017.01.009_b0275","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-14-0683","article-title":"Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma","volume":"20","author":"Ok","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0280","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"Gorgun","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0285","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0290","unstructured":"Gatalica Z, Bilalovic N, Vranic S, Arguello D, Reddy S, Ghosh N. PD-L1 and PD1 Expression in Lymphomas. 57th ASH annual meeting. 2015; December 7, 2015: Abstract 3899."},{"key":"10.1016\/j.ctrv.2017.01.009_b0295","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0300","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0305","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3324\/haematol.10864","article-title":"Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma","volume":"92","author":"Roncador","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2017.01.009_b0310","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0315","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/PAS.0b013e318165b0d6","article-title":"PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Nam-Cha","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0320","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","article-title":"PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0325","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood-2015-08-663997","article-title":"Cell-specific PD-L1 expression in DLBCL","volume":"126","author":"Boussiotis","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0330","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0335","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0340","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7555","article-title":"Pembrolizumab for relapsed\/refractory classical Hodgkin lymphoma (R\/R cHL): phase 2 KEYNOTE-087 study","volume":"34","author":"Chen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0345","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8010","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): final efficacy and safety analysis","volume":"34","author":"Mateos","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0350","doi-asserted-by":"crossref","unstructured":"San Miguel J, Mateos M-V, Shah JJ, Ocio EM, Rodriguez-Otero P, Reece D, et al. Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed\/Refractory Multiple Myeloma (RRMM): Keynote-023. 57th ASH annual meeting. 2015; December 7: Abstract 505.","DOI":"10.1182\/blood.V126.23.505.505"},{"key":"10.1016\/j.ctrv.2017.01.009_b0355","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0360","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7535","article-title":"Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)\u2013A phase 2 study","volume":"34","author":"Younes","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2017.01.009_b0365","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e19018","article-title":"Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): an interim analysis","volume":"34","author":"Hatake","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0370","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0375","unstructured":"United States Securities and Exchange Commission, accessed at <https:\/\/www.sec.gov\/Archives\/edgar\/data\/1011835\/000119312516436201\/d131505d8k.htm>; [accessed 16.09.06]."},{"key":"10.1016\/j.ctrv.2017.01.009_b0380","unstructured":"U.S. FDA Lifts Partial Clinical Hold on Medivation\u2019s Pidilizumab, accessed at <http:\/\/www.fiercebiotech.com\/biotech\/u-s-fda-lifts-partial-clinical-hold-on-medivation-s-pidilizumab>; [accessed 16.09.06]."},{"key":"10.1016\/j.ctrv.2017.01.009_b0385","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0390","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0395","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-3510","article-title":"Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-\/-IL2Rgammanull immunodeficient mice","volume":"75","author":"Sanmamed","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2017.01.009_b0400","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2017.01.009_b0405","doi-asserted-by":"crossref","first-page":"e62924","DOI":"10.1371\/journal.pone.0062924","article-title":"Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2017.01.009_b0410","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2017.01.009_b0415","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.11546","article-title":"4SC-202: epigenetic modulation to pave the way for checkpoint inhibition","volume":"34","author":"Kohlhof","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0420","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e19012","article-title":"Rate of complete metabolic responses to immune checkpoint inhibitors in extremely heavily pre-treated patients with classical Hodgkin\u2019s lymphoma and immunoepigenetic priming","volume":"34","author":"Falchi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0425","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.01.009_b0430","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10072","article-title":"FAK\/PYK2 promotes the Wnt\/beta-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3beta","volume":"4","author":"Gao","year":"2015","journal-title":"Elife."},{"key":"10.1016\/j.ctrv.2017.01.009_b0435","doi-asserted-by":"crossref","unstructured":"Wang Y, Ring JE, Sprott K, Weaver DT, Pachter JA. FAK\/PYK2 inhibition enhances immune checkpoint inhibitor efficacy. In: AACR annual meeting; April 17, 2016; New Orleans, USA, Abstract 568; 2016.","DOI":"10.1158\/1538-7445.AM2016-568"},{"key":"10.1016\/j.ctrv.2017.01.009_b0440","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2014-03-563981","article-title":"Pyk2 promotes tumor progression in multiple myeloma","volume":"124","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0445","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0450","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e14012","article-title":"Anti-PD-1 to enhance NK-cell cytotoxicity towards CD30+ Hodgkin lymphoma induced by CD30\/CD16A TandAb AFM13","volume":"34","author":"Treder","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0455","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2017.01.009_b0460","doi-asserted-by":"crossref","unstructured":"Quah MY, Wong Y, Andtbacka R, Au G, Shafren DR. Elevated immune activity following an anticancer combination therapy of a novel oncolytic immunotherapeutic agent, CAVATAK (Coxsackievirus A21), and immune checkpoint blockade. In: AACR annual meeting; April 18, 2016; New Orleans, USA, Abstract 2341; 2016.","DOI":"10.1158\/1538-7445.AM2016-2341"},{"key":"10.1016\/j.ctrv.2017.01.009_b0465","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.01.009_b0470","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0475","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/annonc\/mdw141","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"27","author":"Naidoo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0480","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8032","article-title":"Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)","volume":"33","author":"Rizvi","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0485","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8064","article-title":"Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC)","volume":"32","author":"McLaughlin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.01.009_b0490","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7\u2013H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2017.01.009_b0495","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1002\/eji.200324270","article-title":"Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis","volume":"33","author":"Rodig","year":"2003","journal-title":"Eur J Immunol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721730018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721730018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T20:56:37Z","timestamp":1658609797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721730018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":99,"alternative-id":["S030573721730018X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.01.009","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the programmed death-1 pathway in lymphoid neoplasms","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}